Effect of Thrombopoietin Receptor Agonist on Pregnant Mice [PDF]
Pharmaceutics, 2022 Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity.
Kensaku Nakai +9 more
doaj +5 more sources
A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient [PDF]
Therapeutic Advances in Hematology, 2022 This report describes the first case of splenic injury in a patient with p.V1316M-associated von Willebrand disease type 2B (VWD2B) with chronic thrombocytopenia, successfully treated with nonoperative management including von Willebrand factor (VWF ...
Caterina Casari +8 more
doaj +3 more sources
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review [PDF]
Therapeutic Advances in Hematology, 2021 The treatment of immune thrombocytopenia (ITP) in adults has evolved rapidly over the past decade. The second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag are approved for the treatment of chronic ITP ...
Nikki Agarwal, Ankit Mangla
doaj +3 more sources
Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia [PDF]
BMC Cancer, 2023 Background Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate.
Jiwon Shin +7 more
doaj +2 more sources
An Analysis of the Serum Metabolomic Profile for the Radiomitigative Effect of the Thrombopoietin Receptor Agonist Romiplostim in Lethally Whole-Body-Irradiated Mice [PDF]
Metabolites, 2022 The thrombopoietin receptor agonist romiplostim (RP) was recently approved by the US Food and Drug Administration for improving survival in patients acutely exposed to myelosuppressive doses of radiation. Our previous studies with mice have shown that RP
Yoshiaki Sato +2 more
doaj +2 more sources
Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia [PDF]
Research Results in Pharmacology, 2023 Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy in children and prescribed for chronic ITP refractory to first-line therapy.
Olga S. Levchenkova +4 more
doaj +2 more sources
Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS [PDF]
International Journal of Analytical Chemistry, 2020 Lusutrombopag is a second oral thrombopoietin (TPO) receptor agonist that selectively acts on human TPO receptors. In the study, UPLC-MS/MS was used to establish a selective and sensitive method to determine lusutrombopag with poziotinib as IS (internal ...
Bo Wang +10 more
doaj +2 more sources
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia [PDF]
Therapeutic Advances in Hematology, 2019 Primary immune thrombocytopenia (ITP) is a bleeding disorder that conventionally has been treated with steroids or other immunosuppressive treatments.
José R. González-Porras +2 more
doaj +2 more sources
Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging [PDF]
Pharmacology Research & PerspectivesEnvironmental stressors, such as ionizing radiation, accelerate aging by causing DNA damage and triggering pathways that lead to cell cycle arrest, apoptosis, and subsequent inflammation.
Masaru Yamaguchi +3 more
doaj +2 more sources
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. [PDF]
Cells, 2019 The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs.
Vogel JU +10 more
europepmc +2 more sources